Recruiting

Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension

ClinicalTrials.gov IDNCT06804122

PhaseNA

Enrollment20

SponsorTampere Heart Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Pulmonary Arterial Hypertension

About this study

Pulmonary arterial hypertension (PAH) is a rare and severe disease characterized by elevation of pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR) due to the narrowing of small pulmonary arteries. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) recommend supervised exercise-based rehabilitation as part of the treatment of PAH patients alongside optimal medical therapy (Level of evidence A, Class of recommendation I). Studies on exercise-based rehabilitation for PAH patients are limited, and most interventions have been conducted at least partially in hospital settings. Unlike more common cardiovascular diseases, there are no detailed international exercise guidelines tailored specifically for PAH patients. This study aims to verify that a group-based outpatient rehabilitation protocol suitable for the Finnish healthcare system improves exercise capacity, quality of life, and physical activity of PAH patients and is safe for appropriately selected patients. Additionally, the study aims to determine whether PAH patients adhere to regular exercise training and whether physical activity increases in the long term. The goal is to assess whether an outpatient rehabilitation protocol, designed for the Finnish healthcare system, can achieve similar results to those observed in previous international studies. The primary outcome measure is the change in the six-minute walking distance (6MWD) compared to the patient's baseline. Long-term 6MWD data are often available for patients. The 6MWD is the most commonly used primary outcome in randomized and controlled PAH drug trials, and improvements in this test have been the basis for drug approvals. An improvement of 33 meters in the 6MWD is considered clinically significant, and the goal is to achieve this change with group-based outpatient rehabilitation. Secondary outcomes include changes in quality of life (SF-36), WHO functional class, NT-proBNP levels, echocardiographic parameters, ESC/ERS risk-stratification score (four-strata model), muscle strength, respiratory measures, balance, daily step count, and insomnia severity.

Interventions

Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION — Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.

Primary outcomes

Change in six-minute walking test result (12 weeks)

Eligibility information

Inclusion Criteria: * Adults over 18 years old residing in Tampere or nearby municipalities. * WHO functional classification II-III. * Commitment to the exercise program. * Stable disease condition with no PAH medication changes in the two months prior. * No recent syncope or arrhythmias causing symptoms within the past two months. Exclusion Criteria: * Severe pulmonary disease or left ventricular failure (HFrEF). * Pregnancy. * Severe congenital heart defect (Eisenmenger syndrome). * Severe liver disease. * Acute inflammatory condition. * Severe anemia (hemoglobin ≤ 75% of the lower reference limit). * Systolic blood pressure below 85 mmHg. * Recent syncope. * Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues. * Untreated severe arrhythmias. * Changes in PAH medication during the rehabilitation program.

Study locations

Tampere Heart Hospital, Tampere, Pirkanmaa 33300 Finland

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.